Home » Topics » BioWorld Science

BioWorld Science
RSS

ReveraGen presents 18-month data on vamorolone in Duchenne muscular dystrophy

Oct. 7, 2019

Positive phase II data presented for lurbinectedin in malignant pleural mesothelioma

Oct. 7, 2019

GSK begins first-in-human study of rabies vaccine GSK-3903133A

Oct. 7, 2019

FDA approves Aklief cream for topical treatment of acne

Oct. 7, 2019

Main function of Parkinson's gene is in inflammation

Oct. 7, 2019

Shire Human Genetic Therapies presents new kallikrein B inhibitors

Oct. 7, 2019

Keeping score by DRUP, not in dribs and drabs

Oct. 7, 2019

Arbutus Biopharma patents HBsAg secretion inhibitors

Oct. 7, 2019

New GBP1 and/or GBP1/PIM1 interaction inhibitors discovered at Stanford University

Oct. 7, 2019

Peptide Logic awarded NIH HEAL initiative grant

Oct. 7, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.